Angiex’s Phase I Cancer Study Bolstered by Abzena’s Clinical Trial Support
Angiex has advanced its Phase I cancer study with essential clinical trial materials provided by Abzena, a global leader in biopharmaceutical development and manufacturing. This collaboration supports the development of Angiex’s AGX101, a TM4SF1-targeted antibody-drug conjugate (ADC) designed to treat aggressive cancers by focusing on tumor blood vessels. The Phase I trial is a crucial step in evaluating the safety and potential efficacy of this innovative therapy.
Pharmaceutical Outsourcing covered this milestone, emphasizing the significance of Abzena’s role in enabling Angiex to move forward with its clinical trial. As a trusted source for pharmaceutical outsourcing and development news, Pharmaceutical Outsourcing provides insight into the strategic partnerships that are essential for bringing groundbreaking therapies like AGX101 to patients. Their coverage highlights the critical impact of CDMOs like Abzena in advancing drug development.